Peer-Reviewed Journal Details
Mandatory Fields
Ridnour, LA,Cheng, RYS,Switzer, CH,Heinecke, JL,Ambs, S,Glynn, S,Young, HA,Trinchieri, G,Wink, DA
2013
March
Clinical Cancer Research
Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment-Poor Prognosis or New Therapeutic Opportunity
Published
()
Optional Fields
APOPTOSIS-INDUCING LIGAND NITRIC-OXIDE SYNTHASE UP-REGULATION TOPICAL IMIQUIMOD SUPPRESSOR-CELLS CANCER CELLS EXPRESSION TLR4 PROMOTES DIFFERENTIATION
19
1340
1346
Numerous reports have described Toll-like receptor (TLR) expression in the tumor microenvironment as it relates to cancer progression, as well as their involvement in inflammation. While TLRs mediate immune surveillance, clinical studies have associated TLR expression in the tumor with poor patient survival, indicating that TLR expression may affect cancer treatment and survival. This review will examine mechanisms in which TLR activation upregulates protumorigenic pathways, including the induction of inducible nitric oxide synthase (iNOS2) and COX2, which in turn increase TLR expression and promote a feed-forward loop leading to tumor progression and the development of more aggressive tumor phenotypes. These propagating loops involve cancer cell, stroma, and/or immune cell TLR expression. Because of abundant TLR expression in many human tumors, several TLR agonists are now in clinical and preclinical trials and some have shown enhanced efficacy when used as adjuvant with radiation, chemotherapy, or cancer vaccines. These findings suggest that TLR expression influences cancer biology and therapeutic response, which may involve specific interactions within the tumor microenvironment, including mediators of inflammation such as nitric oxide and the arachidonic acid signaling pathways. Clin Cancer Res; 19(6); 1340-6. (C) 2012 AACR.
DOI 10.1158/1078-0432.CCR-12-0408
Grant Details
Publication Themes